Africa Samantha Reynoso Roa

Dr. Africa Samantha Reynoso Roa

Departamento de Fisiología, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
LALuis Ricardo Balleza Alejandri
Luis Ricardo Balleza Alejandri
Emiliano Peña-DuránEmiliano Peña-Durán
Emiliano Peña-Durán
Alberto Beltrán-RamírezAlberto Beltrán-Ramírez
Alberto Beltrán-Ramírez
ARAfrica Samantha Reynoso Roa
Africa Samantha Reynoso Roa
LSLuis Daniel Sánchez-Abundis
Luis Daniel Sánchez-Abundis
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
The human microbiome, a complex ecosystem of bacteria, viruses, and protozoans living in symbiosis with the host, plays a crucial role in human health, influencing everything from metabolism to immune function. Dysbiosis, or an imbalance in this ecosystem, has been linked to various health issues, including diabetes and gestational diabetes (GD). In diabetes, dysbiosis affects the function of adipose tissue, leading to the release of adipokines and cytokines, which increase inflammation and insulin resistance. During pregnancy, changes to the microbiome can exacerbate glucose intolerance, a common feature of GD. Over the past years, burgeoning insights into the gut microbiota have unveiled its pivotal role in human health. This article comprehensively reviews literature from the last seven years, highlighting the association between gut microbiota dysbiosis and GD, as well as the metabolism of antidiabetic drugs and the potential influences of diet and probiotics. The underlying pathophysiological mechanisms discussed include the impact of dysbiosis on systemic inflammation and the interplay with genetic and environmental factors. By focusing on recent studies, the importance of considering microbial health in the prevention and treatment of GD is emphasized, providing insights into future research directions and clinical applications to improve maternal–infant health outcomes.

2 April 2025 in Life
Verified
Journal Article
Open access
PDF file
ARAfrica Samantha Reynoso Roa
Africa Samantha Reynoso Roa
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio
EMEzequiel Magallón-Gastélum
Ezequiel Magallón-Gastélum
TGTrinidad García-Iglesias
Trinidad García-Iglesias
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
TCTeresa Arcelia Garcia Cobián
Teresa Arcelia Garcia Cobián
Resistin is an adipokine produced in adipose tissue with pro-inflammatory properties, whose elevation has been associated with insulin resistance and diabetes. Over the past years, significant research has explored the pathophysiological mechanisms involving resistin, utilizing various in vitro and in vivo models. Additionally, numerous clinical studies have aimed to establish a correlation between resistin and the development and progression of macrovascular and microvascular complications in type 2 diabetes. This narrative review summarizes in vitro, in vivo, and human studies published in English since the discovery of resistin in 2001 to the present, examining the role of this adipokine in the pathophysiology of macrovascular and microvascular complications in in vivo and in vitro T2D models, as well as the clinical evidence supporting its use as a biochemical marker in patients with these conditions. The results exhibit considerable heterogeneity and appear to be dependent on the experimental model or population studied. While experimental evidence supports resistin’s involvement at the cellular and molecular levels in the pathogenesis of these complications, current clinical evidence remains insufficient to justify its use as a biochemical marker for either diagnosis or prognosis. Therefore, further well-designed studies are required to elucidate resistin’s potential role in the clinical setting.

Verified
Journal Article
Open access
PDF file
LALuis Ricardo Balleza Alejandri
Luis Ricardo Balleza Alejandri
FGFernando Grover-Páez
Fernando Grover-Páez
ECErick González Campos
Erick González Campos
CBCarlos G. Ramos Becerra
Carlos G. Ramos Becerra
EMErnesto Germán Cardona Muñoz
Ernesto Germán Cardona Muñoz
CRClaudia Yanette Galán Ruíz
Claudia Yanette Galán Ruíz
Aim: To assess the acute effect of empagliflozin versus dapagliflozin administration on flow-mediated vasodilation in patients with type 2 diabetes mellitus. Design: A double-blind clinical trial, at the Experimental and Clinical Therapeutics Institute, University Health Sciences Center, at the Universidad de Guadalajara, in inpatients with T2D according to the 2023 ADA criteria. Methods: Thirty patients (15 males and 15 females), aged between 35 and 65 years, were included in this study, according to the 2023 ADA criteria. The eligible patients were randomly assigned to three groups: empagliflozin 25 mg once daily, dapagliflozin 10 mg once daily, or placebo once daily. Anthropometric parameters were taken using validated techniques. FMD was measured using a high-resolution semiautomatic ultrasound UNEX-EF 38G (UNEX Co., Ltd., Nagoya, Japan). Arterial tension was determined with the OMRON electronic digital sphygmomanometer (HEM 907 XL, Kyoto, Japan). Results: The group of patients who received empagliflozin had a significantly lower baseline flow-mediated dilation (FMD) compared to the group receiving dapagliflozin (p = 0.017); at the end of this study, the empagliflozin group achieved a comparable FMD to the dapagliflozin group (p = 0.88). Conclusion: After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.


12 November 2025 in Diabetology
Verified
Journal Article
Open access
PDF file
ARAfrica Samantha Reynoso Roa
Africa Samantha Reynoso Roa
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio
ACAraceli Castillo-Romero
Araceli Castillo-Romero
TGTrinidad García-Iglesias
Trinidad García-Iglesias
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
TCTeresa Arcelia Garcia Cobián
Teresa Arcelia Garcia Cobián
Background/Objectives: Insulin resistance is a major public health issue in Mexico, closely linked to obesity, prediabetes, and type 2 diabetes. The euglycemic–hyperinsulinemic clamp is the diagnostic gold standard but is impractical for routine use. The triglyceride–glucose (TyG) index has been proposed as a simple alternative validated in diverse populations. We aimed to assess the utility of TyG relative to HOMA-IR and QUICKI as an early diagnostic tool in young Mexican adults. Methods: We performed an analytical cross-sectional study in young adults. Clinical, anthropometric, and fasting biochemical variables were collected to compute TyG. We compared TyG with HOMA-IR and QUICKI and evaluated diagnostic performance using receiver operating characteristic analysis to estimate area under the curve (AUC) and identify the optimal cut-off. Results: We analyzed 115 participants; 66.9% were insulin resistant by HOMA-IR, 79.1% by QUICKI, and 42.6% by TyG. TyG showed significant associations with anthropometric and biochemical measures. Diagnostic performance was good (AUC 0.707 vs. HOMA-IR; 0.960 vs. QUICKI). The optimal cut-off was 4.38, yielding sensitivity of 70.1% and specificity of 68.4% for diagnosing insulin resistance compared with HOMA-IR. Conclusions: The TyG index appears to be a useful, accessible, and cost-effective biomarker for early detection of insulin resistance in young Mexican adults. Its implementation could facilitate earlier diagnosis and prevention of cardiometabolic complications. Longitudinal, multicenter studies are warranted to establish population-specific reference values and to confirm its predictive value for adverse outcomes.

29 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LALuis Ricardo Balleza Alejandri
Luis Ricardo Balleza Alejandri
Emiliano Peña-DuránEmiliano Peña-Durán
Emiliano Peña-Durán
Alberto Beltrán-RamírezAlberto Beltrán-Ramírez
Alberto Beltrán-Ramírez
ARAfrica Samantha Reynoso Roa
Africa Samantha Reynoso Roa
LSLuis Daniel Sánchez-Abundis
Luis Daniel Sánchez-Abundis
DSDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
Over the past years, burgeoning insights into the gut microbiota have unveiled its pivotal role in human health, influencing everything from metabolism to immune function. This article comprehensively reviews literature from the last seven years to dissect the link between gut microbiota and gestational diabetes (GD), a condition of glucose intolerance manifesting during pregnancy with long-term implications for both mother and offspring. Through detailed analysis, we highlight how alterations in the composition and function of the gut microbiota may contribute to the development of GD by influencing insulin resistance and glucose homeostasis. The underlying pathophysiological mechanisms, including dysbiosis and its impact on systemic inflammation, as well as the interplay with genetic, epigenetic, and environmental factors, are discussed. Furthermore, we review current and potential microbiota-targeted interventions, such as probiotic use, and their capability to modify GD risk and management. With a focus on recent studies, this article underscores the significance of considering microbial health in the prevention and treatment of GD, offering insights into future research directions and clinical applications to improve maternal-infant health outcomes.